620112-78-9
中文名稱
ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亞甲基]-2-苯并噻唑乙腈
英文名稱
alpha-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile
CAS
620112-78-9
分子式
C26H18N4O2S
分子量
450.51
MOL 文件
620112-78-9.mol
更新日期
2025/01/07 08:45:03
620112-78-9 結(jié)構(gòu)式
基本信息
中文別名
RGS抑制劑(CCG-63802)ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亞甲基]-2-苯并噻唑乙腈
英文別名
CCG-63802CCG 63802
CCG63802
(E)-2-(Benzo[d]thiazol-2-yl)-3-(9-methyl-4-oxo-2-(m-tolyloxy)-4H-pyrido[1,2-a]pyrimidin-3-yl)a
(E)-2-(Benzo[d]thiazol-2-yl)-3-(9-methyl-4-oxo-2-(m-tolyloxy)-4H-pyrido[1,2-a]pyrimidin-3-yl)acry
α-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile
2-Benzothiazoleacetonitrile, α-[[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-
alpha-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile
(2E)-2-(1,3-Benzothiazol-2-yl)-3-[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]acrylonitrile
物理化學(xué)性質(zhì)
沸點547.9±60.0 °C(Predicted)
密度1.31
儲存條件Sealed in dry,Store in freezer, under -20°C
溶解度Limited solubility, soluble in DMSO
酸度系數(shù)(pKa)-0.42±0.70(Predicted)
形態(tài)固體
顏色黃色
ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亞甲基]-2-苯并噻唑乙腈價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | HY-70074 | ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亞甲基]-2-苯并噻唑乙腈 CCG-63802 | 620112-78-9 | 5mg | 660元 |
| 2024/11/08 | HY-70074 | ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亞甲基]-2-苯并噻唑乙腈 CCG-63802 | 620112-78-9 | 10mg | 1100元 |
| 2024/11/08 | HY-70074 | ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亞甲基]-2-苯并噻唑乙腈 CCG-63802 | 620112-78-9 | 50mg | 3520元 |
常見問題列表
生物活性
CCG-63802 是一種選擇性，可逆變構(gòu)的 G 蛋白信號調(diào)節(jié)子 RGS4 抑制劑。CCG-63802 與 RGS4 特異性結(jié)合并阻斷 RGS4-Gαo 相互作用，IC50 值為 1.9 μM。靶點
|
RGS4 1.9 μM (IC 50 ) |
體外研究
CCG-63802 (5 μM) inhibits regulators of G-protein signaling (RGS) proteins in the presence of BK (bradykinin) and 8-Br-cGMP (membrane-permeable analogue of cGMP), HEK-293 cells start to depolarize again.
體內(nèi)研究
CCG-63802 (0.05 mg/kg; intratracheal administration; once per week; 90 days) reduces RGS4 protein expression, leading to partially abrogate the attenuating effect of PGZ on airway inflammation, hyperresponsiveness (AHR), and remodeling.
| Animal Model: | Forty female BALB/c mice aged 6-8 week old |
| Dosage: | 0.05 mg/kg |
| Administration: | Intratracheal administration; once per week; 90 days |
| Result: | CCG 63802 treatment in OVA +PGZ + CCG group significantly reduced RGS4 protein expression compared to OVA + PGZ group (P < 0.05) |